{"name":"Fennec Pharmaceuticals","slug":"fennec","ticker":"FENC","exchange":"NASDAQ","domain":"fennecpharma.com","description":"Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.","hq":"Research Triangle Park, NC / Canada","founded":0,"employees":"35","ceo":"Rostislav Raykov","sector":"Specialty Pharma / Supportive Care","stockPrice":8.84,"stockChange":2.07,"stockChangePercent":30.58,"marketCap":"$307M","metrics":{"revenue":44642000,"revenueGrowth":73.8,"grossMargin":91.6,"rdSpend":250000,"netIncome":-9741000,"cash":36788000,"dividendYield":0,"peRatio":9.8,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"PEDMARK patent cliff ($10.0M at risk)","drug":"PEDMARK","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Fennec Pharmaceuticals reported its fourth quarter and full year 2023 financial results, with revenue of $1.4 million and a net loss of $14.1 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Fennec Pharmaceuticals Announces Collaboration with the National Cancer Institute","summary":"Fennec Pharmaceuticals announced a collaboration with the National Cancer Institute to develop a new treatment for chemotherapy-induced neuropathic pain.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"PEDMARK Receives FDA Approval for the Treatment of Chemotherapy-Induced Neuropathic Pain","summary":"The FDA approved PEDMARK for the treatment of chemotherapy-induced neuropathic pain in patients with cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE5faFVrMXlXbXRjdzlPRGxrVU1qNDdabk93TG1Mb19ta0k4T0lDQmZ2NW9jaWpqMDYzXzFMQ3VBVUJHVlpIeGZaTFltdVNWaDJKSzlHQjctVGJBT0NhTFZjd1o4RdIBY0FVX3lxTE5faFVrMXlXbXRjdzlPRGxrVU1qNDdabk93TG1Mb19ta0k4T0lDQmZ2NW9jaWpqMDYzXzFMQ3VBVUJHVlpIeGZaTFltdVNWaDJKSzlHQjctVGJBT0NhTFZjd1o4RQ?oc=5","date":"2026-04-07","type":"trial","source":"Bitget","summary":"Fennec Pharma’s Latest Adult Trial May Trigger a Revaluation—Provided It Overcomes Earnings-Related Plateau - Bitget","headline":"Fennec Pharma’s Latest Adult Trial May Trigger a Revaluation—Provided It Overcomes Earnings-Related Plateau","sentiment":"neutral"},{"date":"2026-04-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQOTRPRzQ2WkxaMzlMQktqbWJTZ1RnNmxDcG5uekNCNFljMVFzOFhQWTRrak84dFFyd2NTdG9JSmktN0dEYTNoRGs1TFNNelh2MUR5SF9MYlBfVDNFdFJjakt3Y3JXcFk1TzN3OThEMWMyMHVGeGtmNlVOZ0Q3TlBtMkF4OVJWU3dNNWJYd0xyMW9GVkJDYUZ0YTRFY29IWW1PNWRIS19ISHF0dnVrUzZNemR6NWhpS3lyY0YyZw?oc=5","date":"2026-04-02","type":"pipeline","source":"Stock Titan","summary":"CMO at Fennec (NASDAQ: FENC) receives 120,000 stock options award - Stock Titan","headline":"CMO at Fennec (NASDAQ: FENC) receives 120,000 stock options award","sentiment":"neutral"},{"date":"2026-03-27","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNckgzYUVqLUJBM1ROeFpqMHMxY0FIbHZFQVJTTW1vWE1mVGFEd0hoZmVoeUVVbHp2dk1jVnZOcVMzT1Y2bWFSUE13QlBfMFk1VkRYQ1IzZEFaZ0k4aGl4MWdzWEo1UnRlZXd3T3YzYzlTRDhBdmRmZ0ozWUl4a3VhR0pQS3JGTVFFTFEzeW0wdHRUaHBUT0pjTFctMURzSF9aU2hwQUJaVDNRUG5Demp2ZkNXMW5XdmpBOFNfM0lR?oc=5","date":"2026-03-18","type":"pipeline","source":"Stock Titan","summary":"Fennec schedules March 24 call to unveil full-year 2025 numbers - Stock Titan","headline":"Fennec schedules March 24 call to unveil full-year 2025 numbers","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-16","type":"patent","source":"The Manila Times","summary":"Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation - The Manila Times","headline":"Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation","sentiment":"neutral"},{"date":"2026-03-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNb2ZVN25EZDVmZHZvUER6QmpTN1ZTLVVfQVhqMENXOVRSYlJFYjhpRmtjTld3YkVoSk1lV0JiLU1Gc1JxN08tenNNUXNTaGwtbTk1SlNMSkFNNS15YnRmM0tsMTBkQnBhRWxUMVUtdkFGZHFXdFRTNk9wdEZydjAzR0ZMMkY0Um95U0lZWDlEVEQ4UE9MWVBfMU5jN3JWQmN6a0xDdG40VFU5MVF2eUI0dVhCUVNYb215?oc=5","date":"2026-02-20","type":"pipeline","source":"Stock Titan","summary":"Cancer drug timing tweak shows promise for preserving hearing - Stock Titan","headline":"Cancer drug timing tweak shows promise for preserving hearing","sentiment":"neutral"},{"date":"2026-02-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQVjR1UjM5aDVJcWNkdUszWm03RUczVmtPTnFPUFNFY3JrbzVqaUd4aFhIc1JDcDdfbzlqdHdoS3pIM2RoY2FlVktHRTBuY0RPZDF5NXRBX1dwRXVDQmxvQTVOV1RwcktObzBXa1dqak5IeEhrc3hSeUFUaUE4MGRnNjIxcEM3RkN0UFVOODhiZjdlM1VmTEE0TGhoQ3ZuT0loQmxMWUZxTEpxd01VZXV4MQ?oc=5","date":"2025-12-21","type":"pipeline","source":"Seeking Alpha","summary":"Fennec Pharmaceuticals: A Compelling Single-Asset Growth Story For 2026 (NASDAQ:FENC) - Seeking Alpha","headline":"Fennec Pharmaceuticals: A Compelling Single-Asset Growth Story For 2026 (NASDAQ:FENC)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOVnZHbDc0dEdqNEF5MzZCSkh6eWd2QlJDZjN6VnZOM1g0THAtNnE2b1NJUC1rSFdWMWFFQXEwaUhIaWFVWDFlQ09DdndYb0pDZFViWHl3T0pDR3Q4V0lzRlRuc2FuV3pwUFIySkpnenBWSkY3VE9jSWVxcFRsUnhiUUljSVZJTXAxMlJvYkk4UUJWRHp5eFE?oc=5","date":"2025-09-05","type":"pipeline","source":"Nasdaq","summary":"Fennec Pharmaceuticals Rings the Nasdaq Stock Market Closing Bell - Nasdaq","headline":"Fennec Pharmaceuticals Rings the Nasdaq Stock Market Closing Bell","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPMmRKUTZBYjZvTlRKSHJNM1E0bVl4WjFwQUpVVldzMDIwNXMtRFo0blBvZ0ZFbHlnaGhjY3FFbk9obEprQjBxbW9sWmY5dV9HT0NaeUMxZmxhTk05WklCTk9pSnVUcGVkZFgwQWxnTG9DZzVMWFhMTk5oZTR0ZWo5VnFseFJlLXpTVjN4c083WENIYUZjaVRxQmdRanNVbFAya2liWFFhcw?oc=5","date":"2024-10-30","type":"pipeline","source":"The Business Journals","summary":"RTP drugmaker appoints new execs following CEO swap - The Business Journals","headline":"RTP drugmaker appoints new execs following CEO swap","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNZzB6NE1fSENkX0l6XzZNSV81VDBxTTJsVnZtb1hmbmZiVFdFWGQwU0s4REpCYVI0eHdmRmVDTm9LLUFCa0lwdm5RcDRGRllBeTB6d1plbFNFZjlPX1ZJd3RjNVVKTGZjTkhsdHMzcF9SYVR4NmVyR0hJbExLY0tzckNXWkRFTDA4UlVvckQ2djFCb3VQ?oc=5","date":"2024-10-28","type":"pipeline","source":"The Pharma Letter","summary":"Fennec Pharmaceuticals expands leadership team - The Pharma Letter","headline":"Fennec Pharmaceuticals expands leadership team","sentiment":"neutral"}],"patents":[{"drugName":"PEDMARK","drugSlug":"amifostine","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":10000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Merck & Co.","Bristol-Myers Squibb","Eli Lilly and Company"],"therapeuticFocus":["Supportive Care","Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":44642000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":44642000,"period":"2025-12-31"},{"value":47538000,"period":"2024-12-31"},{"value":47538000,"period":"2024-12-31"},{"value":21252000,"period":"2023-12-31"},{"value":21252000,"period":"2023-12-31"}],"grossProfit":40878000,"grossProfitHistory":[{"period":"2025-12-31","value":40878000},{"period":"2024-12-31","value":44354000},{"period":"2023-12-31","value":19993000},{"period":"2022-12-31","value":1449000}],"rdSpend":250000,"rdSpendHistory":[{"period":"2025-12-31","value":250000},{"period":"2024-12-31","value":307000},{"period":"2023-12-31","value":56000},{"period":"2022-12-31","value":3531000}],"sgaSpend":46910000,"operatingIncome":-6346000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-6346000},{"period":"2024-12-31","value":2479000},{"period":"2023-12-31","value":-13058000},{"period":"2022-12-31","value":-22738000}],"netIncome":-9741000,"netIncomeHistory":[{"period":"2025-12-31","value":-9741000},{"period":"2024-12-31","value":-436000},{"period":"2023-12-31","value":-16045000},{"period":"2022-12-31","value":-23714000}],"eps":-0.34,"epsHistory":[{"period":"2025-12-31","value":-0.34},{"period":"2024-12-31","value":0},{"period":"2023-12-31","value":-0.6},{"period":"2022-12-31","value":-0.9}],"cash":36788000,"cashHistory":[{"period":"2025-12-31","value":36788000},{"period":"2024-12-31","value":26634000},{"period":"2023-12-31","value":13269000},{"period":"2022-12-31","value":23774000}],"totalAssets":70551000,"totalLiabilities":null,"totalDebt":0,"equity":35472000,"operatingCashflow":-12473000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-12473000},{"period":"2024-12-31","value":26980000},{"period":"2023-12-31","value":-17143000},{"period":"2022-12-31","value":-18058000}],"capex":null,"capexHistory":[],"freeCashflow":-12473000,"dividendsPaid":null,"buybacks":null,"employees":35,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":14547000,"ebit":-4373000,"ebitda":-4347000,"period":"2025-12-31","revenue":13777000,"epsBasic":-0.17,"netIncome":-4787000,"rdExpense":20000,"epsDiluted":-0.17,"grossProfit":12013000,"operatingIncome":-2580000},{"sga":11962000,"ebit":-52000,"ebitda":-26000,"period":"2025-09-30","revenue":12462000,"epsBasic":-0.02,"netIncome":-638000,"rdExpense":29000,"epsDiluted":-0.02,"grossProfit":11802000,"operatingIncome":-201000},{"sga":11310000,"ebit":-2558000,"ebitda":-2533000,"period":"2025-06-30","revenue":9652000,"epsBasic":-0.11,"netIncome":-3152000,"rdExpense":107000,"epsDiluted":-0.11,"grossProfit":8685000,"operatingIncome":-2732000},{"sga":9092000,"ebit":-573000,"ebitda":-547000,"period":"2025-03-31","revenue":8751000,"epsBasic":-0.04,"netIncome":-1165000,"rdExpense":94000,"epsDiluted":-0.04,"grossProfit":8378000,"operatingIncome":-821000},{"sga":8140000,"ebit":-654000,"ebitda":-628000,"period":"2024-12-31","revenue":7925000,"epsBasic":-0.06,"netIncome":-1985000,"rdExpense":50000,"epsDiluted":-0.06,"grossProfit":7256000,"operatingIncome":-959000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":8.84,"previousClose":6.77,"fiftyTwoWeekHigh":9.92,"fiftyTwoWeekLow":5.65,"fiftyTwoWeekRange":"5.65 - 9.92","fiftyDayAverage":6.84,"twoHundredDayAverage":7.92,"beta":0.91,"enterpriseValue":196608960,"forwardPE":9.8,"priceToBook":8.52,"priceToSales":6.87,"enterpriseToRevenue":4.4,"enterpriseToEbitda":-31.82,"pegRatio":0,"ebitda":-6179333,"ebitdaMargin":-13.8,"freeCashflow":-7332250,"operatingCashflow":-12473000,"totalDebt":0,"debtToEquity":0,"currentRatio":6.37,"returnOnAssets":-6.8,"returnOnEquity":-65.8,"analystRating":"","recommendationKey":"none","numberOfAnalysts":6,"targetMeanPrice":15.17,"targetHighPrice":18,"targetLowPrice":13,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":14.4,"institutionHeldPercent":54.4,"sharesOutstanding":34712756,"floatShares":16961098,"sharesShort":1060249,"shortRatio":7.12,"shortPercentOfFloat":3,"epsTrailing":-0.34,"epsForward":0.9,"revenuePerShare":1.56,"bookValue":1.04,"officers":[{"age":62,"name":"Mr. Jeffrey S. Hackman","title":"CEO & Director"},{"age":50,"name":"Mr. Robert C. Andrade","title":"Chief Financial Officer"},{"age":null,"name":"Dr. Pierre S. Sayad M.S., Ph.D.","title":"Chief Medical Officer"},{"age":null,"name":"Mr. Terry  Evans","title":"Chief Commercial Officer"},{"age":null,"name":"Ms. Christiana  Cioffi M.B.A.","title":"Chief Strategy Officer"},{"age":null,"name":"Mr. Mark  Gowland","title":"Controller"},{"age":null,"name":"Mr. Lei  Fang","title":"President of Pharstat Inc"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.fennecpharma.com","phone":"919 636 4530"}}